AAN has issued a practice guideline update for vaccine-preventable infections and immunizations for individuals with multiple sclerosis (MS). A subcommittee of the AAN — tasked with developing, disseminating and implementing these guidelines — found improvements and additions to the recommendations previously issued in 2002.
From 2011 to 2017, there was an increase in gross annual expenditures on multiple sclerosis (MS) disease-modifying therapies (DMTs), with increased spending mainly driven by increases in per-prescription costs.
Early initiation of highly effective escalation therapies in pediatric patients with MS is associated with reduced cognitive impairment and may prevent cognitive decline.
